Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-02-2022 | Obesity

The endocannabinoid system in the adipose organ

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2022

Abstract

The endocannabinoid system is found in most, if not all, mammalian organs and is involved in a variety of physiological functions, ranging from the control of synaptic plasticity in the brain to the modulation of smooth muscle motility in the gastrointestinal tract. This signaling complex consists of G protein-coupled cannabinoid receptors, endogenous ligands for those receptors (endocannabinoids) and enzymes/transporters responsible for the formation and deactivation of these ligands. There are two subtypes of cannabinoid receptors, CB₁ and CB₂, and two major endocannabinoids, arachidonoylethanolamide (anandamide) and 2-arachidonoyl-sn-glycerol (2-AG), which are produced upon demand through cleavage of distinct phospholipid precursors. All molecular components of the endocannabinoid system are represented in the adipose organ, where endocannabinoid signals are thought to regulate critical homeostatic processes, including adipogenesis, lipogenesis and thermogenesis. Importantly, obesity was found to be associated with excess endocannabinoid activity in visceral fat depots, and the therapeutic potential of normalizing such activity by blocking CB₁ receptors has been the focus of substantial preclinical and clinical research. Results have been mixed thus far, mostly owing to the emergence of psychiatric side effects rooted in the protective functions served by brain endocannabinoids in mood and affect regulation. Further studies about the roles played by the endocannabinoid system in the adipose organ will offer new insights into the pathogenesis of obesity and might help identify new ways to leverage this signaling complex for therapeutic benefit.

Jung KM, Piomelli D. Cannabinoids and Endocannabinoids. In: Pfaff D, Volkow N, editors. Neuroscience in the 21st Century. New York: Springer; 2015. https://doi.org/10.1007/978-1-4614-6434-1_136-1.

Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4(11):873–84. https://doi.org/10.1038/nrn1247.CrossRef

Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–47.CrossRef

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–4. https://doi.org/10.1038/346561a0.CrossRefPubMed

Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5. https://doi.org/10.1038/365061a0.CrossRefPubMed

Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006;46:101–22. https://doi.org/10.1146/annurev.pharmtox.46.120604.141254.CrossRefPubMed

Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017–66. https://doi.org/10.1152/physrev.00004.2003.CrossRefPubMed

Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89(1):309–80. https://doi.org/10.1152/physrev.00019.2008.CrossRefPubMed

Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9. https://doi.org/10.1126/science.1470919.CrossRefPubMed

10.

Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1):89–97. https://doi.org/10.1006/bbrc.1995.2437.CrossRefPubMed

11.

Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83–90. https://doi.org/10.1016/0006-2952(95)00109-d.CrossRefPubMed

12.

Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372(6507):686–91. https://doi.org/10.1038/372686a0.CrossRefPubMed

13.

Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388(6644):773–8. https://doi.org/10.1038/42015.CrossRefPubMed

14.

Piomelli D, Astarita G, Rapaka R. A neuroscientist’s guide to lipidomics. Nat Rev Neurosci. 2007;8(10):743–54. https://doi.org/10.1038/nrn2233.CrossRefPubMed

15.

Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161–202. https://doi.org/10.1124/pr.54.2.161.CrossRefPubMed

16.

Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci. 1995;15(10):6552–61. https://doi.org/10.1523/JNEUROSCI.15-10-06552.1995.CrossRefPubMedPubMedCentral

17.

Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 1997;78(1):43–50. https://doi.org/10.1152/jn.1997.78.1.43.CrossRefPubMed

18.

Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther. 1999;288(3):1357–66.PubMed

19.

Gómez Del Pulgar T, De Ceballos ML, Guzmán M, Velasco G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem. 2002;277(39):36527–33. https://doi.org/10.1074/jbc.M205797200.CrossRefPubMed

20.

Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58(9):1017–30. https://doi.org/10.1002/glia.20983.CrossRefPubMedPubMedCentral

21.

Maccarrone M, Bab I, Bíró T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277–96. https://doi.org/10.1016/j.tips.2015.02.008.CrossRefPubMedPubMedCentral

22.

Kunos G, Tam J. The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol. 2011;163(7):1423–31. https://doi.org/10.1111/j.1476-5381.2011.01352.x.CrossRefPubMedPubMedCentral

23.

DiPatrizio NV, Piomelli D. Intestinal lipid-derived signals that sense dietary fat. J Clin Invest. 2015;125(3):891–8. https://doi.org/10.1172/JCI76302.CrossRefPubMedPubMedCentral

24.

Kunos G, Osei-Hyiaman D. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol. 2008;294(5):G1101–4. https://doi.org/10.1152/ajpgi.00057.2008.CrossRefPubMed

25.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology. 2011;53(1):346–55. https://doi.org/10.1002/hep.24077.CrossRefPubMed

26.

Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423–31. https://doi.org/10.1172/JCI17725.CrossRefPubMedPubMedCentral

27.

Eriksson O, Mikkola K, Espes D, et al. The Cannabinoid Receptor-1 Is an Imaging Biomarker of Brown Adipose Tissue. J Nucl Med. 2015;56(12):1937–41. https://doi.org/10.2967/jnumed.115.156422.CrossRefPubMed

28.

Starowicz KM, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring). 2008;16(3):553–65. https://doi.org/10.1038/oby.2007.106.CrossRef

29.

Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63(4):908–14. https://doi.org/10.1124/mol.63.4.908.CrossRefPubMed

30.

Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91(8):3171–80. https://doi.org/10.1210/jc.2005-2679.CrossRefPubMed

31.

Mehrpouya-Bahrami P, Miranda K, Singh NP, Zumbrun EE, Nagarkatti M, Nagarkatti PS. Role of microRNA in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity. J Biol Chem. 2019;294(19):7669–81. https://doi.org/10.1074/jbc.RA118.005094.CrossRefPubMedPubMedCentral

32.

Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;118(8):2023–8. https://doi.org/10.1111/j.1476-5381.1996.tb15639.x.CrossRefPubMedPubMedCentral

33.

Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: It can go either way. Br J Pharmacol. 2008;153(2):299–308. https://doi.org/10.1038/sj.bjp.0707523.CrossRefPubMed

34.

Pagano C, Pilon C, Calcagno A, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab. 2007;92(12):4810–9. https://doi.org/10.1210/jc.2007-0768.CrossRefPubMed

35.

Roche R, Hoareau L, Bes-Houtmann S, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol. 2006;126(2):177–87. https://doi.org/10.1007/s00418-005-0127-4.CrossRefPubMed

36.

Spoto B, Fezza F, Parlongo G, et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie. 2006;88(12):1889–97. https://doi.org/10.1016/j.biochi.2006.07.019.CrossRefPubMed

37.

Pagano C, Rossato M, Vettor R. Endocannabinoids, adipose tissue and lipid metabolism. J Neuroendocrinol. 2008;20(Suppl 1):124–9. https://doi.org/10.1111/j.1365-2826.2008.01690.x.CrossRefPubMed

38.

Rossi F, Bellini G, Luongo L, et al. Cannabinoid Receptor 2 as Antiobesity Target: Inflammation, Fat Storage, and Browning Modulation. J Clin Endocrinol Metab. 2016;101(9):3469–78. https://doi.org/10.1210/jc.2015-4381.CrossRefPubMed

39.

Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci. 1997;17(4):1226–42. https://doi.org/10.1523/JNEUROSCI.17-04-01226.1997.CrossRefPubMedPubMedCentral

40.

Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 1999;2(4):358–63. https://doi.org/10.1038/7268.CrossRefPubMed

41.

Wei D, Lee D, Cox CD, et al. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S A. 2015;112(45):14084–9. https://doi.org/10.1073/pnas.1509795112.CrossRefPubMedPubMedCentral

42.

Ogura Y, Parsons WH, Kamat SS, Cravatt BF. A calcium-dependent acyltransferase that produces N-acyl phosphatidylethanolamines. Nat Chem Biol. 2016;12(9):669–71. https://doi.org/10.1038/nchembio.2127.CrossRefPubMedPubMedCentral

43.

Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004;279(7):5298–305. https://doi.org/10.1074/jbc.M306642200.CrossRefPubMed

44.

Tsuboi K, Ikematsu N, Uyama T, Deutsch DG, Tokumura A, Ueda N. Biosynthetic pathways of bioactive N-acylethanolamines in brain. CNS Neurol Disord Drug Targets. 2013;12(1):7–16. https://doi.org/10.2174/1871527311312010005.CrossRefPubMed

45.

Serrano A, Pavon FJ, Buczynski MW, et al. Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake. Neuropsychopharmacology. 2018;43(9):1840–50. https://doi.org/10.1038/s41386-018-0055-3.CrossRefPubMedPubMedCentral

46.

Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277(5329):1094–7. https://doi.org/10.1126/science.277.5329.1094.CrossRefPubMed

47.

Nicolussi S, Gertsch J. Endocannabinoid transport revisited. Vitam Horm. 2015;98:441–85. https://doi.org/10.1016/bs.vh.2014.12.011.CrossRefPubMed

48.

Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384(6604):83–7. https://doi.org/10.1038/384083a0.CrossRefPubMed

49.

McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem. 2005;74:411–32.CrossRef

50.

Seal SN, Rose ZB. Characterization of a phosphoenzyme intermediate in the reaction of phosphoglycolate phosphatase. J Biol Chem. 1987;262(28):13496–500.CrossRef

51.

Bennett CF, Balcarek JM, Varrichio A, Crooke ST. Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature. 1988;334(6179):268–70. https://doi.org/10.1038/334268a0.CrossRefPubMed

52.

Bisogno T, Howell F, Williams G, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163(3):463–8. https://doi.org/10.1083/jcb.200305129.CrossRefPubMedPubMedCentral

53.

Jung KM, Sepers M, Henstridge CM, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3:1080. https://doi.org/10.1038/ncomms2045.CrossRefPubMed

54.

Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation [published correction appears in Proc Natl Acad Sci U S A 2002 Oct 15;99(21):13961]. Proc Natl Acad Sci U S A. 2002;99(16):10819–24. https://doi.org/10.1073/pnas.152334899.CrossRefPubMedPubMedCentral

55.

Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007;14(12):1347–56. https://doi.org/10.1016/j.chembiol.2007.11.006.CrossRefPubMedPubMedCentral

56.

Krott LM, Piscitelli F, Heine M, et al. Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation. J Lipid Res. 2016;57(3):464–73. https://doi.org/10.1194/jlr.M065227.CrossRefPubMedPubMedCentral

57.

van Eenige R, van der Stelt M, Rensen PCN, Kooijman S. Regulation of adipose tissue metabolism by the endocannabinoid system. Trends Endocrinol Metab. 2018;29(5):326–37. https://doi.org/10.1016/j.tem.2018.03.001.CrossRefPubMed

58.

Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem. 1997;272(43):27218–23. https://doi.org/10.1074/jbc.272.43.27218.CrossRefPubMed

59.

Nahon KJ, Kantae V, den Haan R, et al. Gene expression of endocannabinoid system components in skeletal muscle and adipose tissue of South Asians and white caucasians with overweight. Obesity (Silver Spring). 2018;26(8):1332–7. https://doi.org/10.1002/oby.22245.CrossRef

60.

You T, Disanzo BL, Wang X, Yang R, Gong D. Adipose tissue endocannabinoid system gene expression: Depot differences and effects of diet and exercise. Lipids Health Dis. 2011;10:194. https://doi.org/10.1186/1476-511X-10-194. Published 2011 Oct 28.CrossRefPubMedPubMedCentral

61.

Zoerner AA, Rakers C, Engeli S, et al. Peripheral endocannabinoid microdialysis: In vitro characterization and proof-of-concept in human subjects. Anal Bioanal Chem. 2012;402(9):2727–35. https://doi.org/10.1007/s00216-012-5729-9.CrossRefPubMed

62.

Mulawa EA, Kirkwood JS, Wolfe LM, et al. Seasonal changes in endocannabinoid concentrations between active and hibernating marmots (Marmota flaviventris). J Biol Rhythms. 2018;33(4):388–401. https://doi.org/10.1177/0748730418777660.CrossRefPubMed

63.

Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci. 2007;64(2):219–29. https://doi.org/10.1007/s00018-006-6445-4.CrossRefPubMed

64.

Ruiz de Azua I, Mancini G, Srivastava RK, et al. Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages. J Clin Invest. 2017;127(11):4148–62. https://doi.org/10.1172/JCI83626.CrossRefPubMedPubMedCentral

65.

Quarta C, Bellocchio L, Mancini G, et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab. 2010;11(4):273–85. https://doi.org/10.1016/j.cmet.2010.02.015.CrossRefPubMed

66.

DiPatrizio NV, Piomelli D. The thrifty lipids: Endocannabinoids and the neural control of energy conservation. Trends Neurosci. 2012;35(7):403–11. https://doi.org/10.1016/j.tins.2012.04.006.CrossRefPubMedPubMedCentral

67.

Suárez J, Rivera P, Aparisi Rey A, et al. Adipocyte cannabinoid CB1 receptor deficiency alleviates high fat diet-induced memory deficit, depressive-like behavior, neuroinflammation and impairment in adult neurogenesis. Psychoneuroendocrinology. 2019;110:104418. https://doi.org/10.1016/j.psyneuen.2019.104418.CrossRefPubMed

68.

Cristancho AG, Lazar MA. Forming functional fat: A growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol. 2011;12(11):722–34. https://doi.org/10.1038/nrm3198. Published 2011 Sep 28.CrossRefPubMedPubMedCentral

69.

Bellocchio L, Cervino C, Vicennati V, Pasquali R, Pagotto U. Cannabinoid type 1 receptor: Another arrow in the adipocytes’ bow. J Neuroendocrinol. 2008;20(Suppl 1):130–8. https://doi.org/10.1111/j.1365-2826.2008.01682.x.CrossRefPubMed

70.

Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8(5):585–9. https://doi.org/10.1038/nn1457.CrossRefPubMed

71.

Giordano A, Frontini A, Cinti S. Convertible visceral fat as a therapeutic target to curb obesity. Nat Rev Drug Discov. 2016;15(6):405–24. https://doi.org/10.1038/nrd.2016.31.CrossRefPubMed

72.

Shapira SN, Seale P. Transcriptional control of brown and beige fat development and function. Obesity (Silver Spring). 2019;27(1):13–21. https://doi.org/10.1002/oby.22334.CrossRef

73.

Maurer S, Harms M, Boucher J. The colorful versatility of adipocytes: white-to-brown transdifferentiation and its therapeutic potential in humans. FEBS J. 2020 Jul 3. doi: https://doi.org/10.1111/febs.15470.

74.

Hardie DG, Schaffer BE, Brunet A. AMPK: An energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol. 2016;26(3):190–201. https://doi.org/10.1016/j.tcb.2015.10.013.CrossRefPubMed

75.

Tedesco L, Valerio A, Dossena M, et al. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: The role of eNOS, p38 MAPK, and AMPK pathways. Diabetes. 2010;59(11):2826–36. https://doi.org/10.2337/db09-1881.CrossRefPubMedPubMedCentral

76.

Cheng CF, Ku HC, Lin H. PGC-1α as a pivotal factor in lipid and metabolic regulation. Int J Mol Sci. 2018;19(11):3447. Published 2018 Nov 2. https://doi.org/10.3390/ijms19113447.

77.

Perwitz N, Wenzel J, Wagner I, et al. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes Metab. 2010;12(2):158–66. https://doi.org/10.1111/j.1463-1326.2009.01133.x.CrossRefPubMed

78.

Deveaux V, Cadoudal T, Ichigotani Y, et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One. 2009;4(6):e5844. https://doi.org/10.1371/journal.pone.0005844. Published 2009 Jun 9.CrossRefPubMedPubMedCentral

79.

Verty AN, Stefanidis A, McAinch AJ, Hryciw DH, Oldfield B. Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. PLoS One. 2015;10(11):e0140592. https://doi.org/10.1371/journal.pone.0140592 Published 2015 Nov 20.CrossRefPubMedPubMedCentral

80.

Silva JE. Physiological importance and control of non-shivering facultative thermogenesis. Front Biosci (Schol Ed). 2011;3:352–71. https://doi.org/10.2741/s156. Published 2011 Jan 1.CrossRef

81.

Verty AN, Evetts MJ, Crouch GJ, McGregor IS, Stefanidis A, Oldfield BJ. The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. Neuropsychopharmacology. 2011;36(7):1349–58. https://doi.org/10.1038/npp.2011.19.CrossRefPubMedPubMedCentral

82.

Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell Biol. 2005;6(3):248–61. https://doi.org/10.1038/nrm1592.CrossRefPubMed

83.

Boon MR, Kooijman S, van Dam AD, et al. Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity. FASEB J. 2014;28(12):5361–75. https://doi.org/10.1096/fj.13-247643.CrossRefPubMed

84.

Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18(1):27–37. https://doi.org/10.1016/j.tem.2006.11.006.CrossRefPubMed

85.

Jung KM, Clapper JR, Fu J, et al. 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab. 2012;15(3):299–310. https://doi.org/10.1016/j.cmet.2012.01.021.CrossRefPubMedPubMedCentral

86.

Cinar R, Iyer MR, Kunos G. The therapeutic potential of second and third generation CB₁R antagonists. Pharmacol Ther. 2020;208:107477. https://doi.org/10.1016/j.pharmthera.2020.107477.CrossRefPubMedPubMedCentral

87.

Hirsch S, Tam J. Cannabis: from a plant that modulates feeding behaviors toward developing selective inhibitors of the peripheral endocannabinoid system for the treatment of obesity and metabolic syndrome. Toxins (Basel). 2019;11(5):275. Published 2019 May 15. https://doi.org/10.3390/toxins11050275.

88.

Tam J, Hinden L, Drori A, Udi S, Azar S, Baraghithy S. The therapeutic potential of targeting the peripheral endocannabinoid/CB₁ receptor system. Eur J Intern Med. 2018;49:23–9. https://doi.org/10.1016/j.ejim.2018.01.009.CrossRefPubMed

89.

Jourdan T, Godlewski G, Kunos G. Endocannabinoid regulation of β-cell functions: Implications for glycaemic control and diabetes. Diabetes Obes Metab. 2016;18(6):549–57. https://doi.org/10.1111/dom.12646.CrossRefPubMedPubMedCentral

90.

Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013;17(4):475–90. https://doi.org/10.1016/j.cmet.2013.03.001.CrossRefPubMed

91.

Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55(11):3053–60. https://doi.org/10.2337/db06-0812.CrossRefPubMed

92.

Côté M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond). 2007;31(4):692–9. https://doi.org/10.1038/sj.ijo.0803539.CrossRef

93.

Di Marzo V, Côté M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, Petrosino S, Alméras N, Després JP. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia. 2009;52(2):213-7. https://doi.org/10.1007/s00125-008-1178-6.

94.

Sarzani R, Bordicchia M, Marcucci P, et al. Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism. 2009;58(3):361–7. https://doi.org/10.1016/j.metabol.2008.10.009.CrossRefPubMed

95.

Bordicchia M, Battistoni I, Mancinelli L, et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism. 2010;59(5):734–41. https://doi.org/10.1016/j.metabol.2009.09.018.CrossRefPubMed

96.

Bennetzen MF. Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options. Dan Med Bull. 2011;58(4):B4269.PubMed

97.

Engeli S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol. 2012;209:357–81. https://doi.org/10.1007/978-3-642-24716-3_17.CrossRef

98.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study [published correction appears in Lancet. 2005 Jul 30-Aug 5;366(9483):370]. Lancet. 2005;365(9468):1389–1397. https://doi.org/10.1016/S0140-6736(05)66374-X.

99.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial [published correction appears in JAMA. 2006 Mar 15;295(11):1252]. JAMA. 2006;295(7):761–775. https://doi.org/10.1001/jama.295.7.761.

100.

Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study [published correction appears in Lancet. 2006 Nov 11;368(9548):1650]. Lancet. 2006;368(9548):1660–1672. https://doi.org/10.1016/S0140-6736(06)69571-8.

101.

Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121–34. https://doi.org/10.1056/NEJMoa044537.CrossRefPubMed

102.

Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology. 2009;56(Suppl 1):235–43. https://doi.org/10.1016/j.neuropharm.2008.07.018.CrossRefPubMed

103.

Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity [published correction appears in J Clin Invest. 2010 Oct 1;120(10):3735]. J Clin Invest. 2010;120(8):2953–2966. https://doi.org/10.1172/JCI42551.

104.

DiPatrizio NV, Joslin A, Jung KM, Piomelli D. Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats. FASEB J. 2013;27(6):2513–20. https://doi.org/10.1096/fj.13-227587.CrossRefPubMedPubMedCentral

105.

Tam J, Cinar R, Liu J, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012;16(2):167–79. https://doi.org/10.1016/j.cmet.2012.07.002.CrossRefPubMed

106.

Cinar R, Godlewski G, Liu J, et al. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology. 2014;59(1):143–53. https://doi.org/10.1002/hep.26606.CrossRefPubMed

107.

Rodríguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414(6860):209–12. https://doi.org/10.1038/35102582.CrossRefPubMed

108.

Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425(6953):90–3. https://doi.org/10.1038/nature01921.CrossRefPubMed

109.

Schwartz GJ, Fu J, Astarita G, et al. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab. 2008;8(4):281–8. https://doi.org/10.1016/j.cmet.2008.08.005.CrossRefPubMedPubMedCentral

110.

LoVerme J, Guzmán M, Gaetani S, Piomelli D. Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue. J Biol Chem. 2006;281(32):22815–8. https://doi.org/10.1074/jbc.M604751200.CrossRefPubMed

111.

Guzmán M, Lo Verme J, Fu J, Oveisi F, Blázquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem. 2004;279(27):27849–54. https://doi.org/10.1074/jbc.M404087200.CrossRefPubMed

112.

Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005;48(8):1147–53. https://doi.org/10.1016/j.neuropharm.2005.02.013.CrossRefPubMed

113.

Laleh P, Yaser K, Abolfazl B, et al. Oleoylethanolamide increases the expression of PPAR-Α and reduces appetite and body weight in obese people: A clinical trial. Appetite. 2018;128:44–9. https://doi.org/10.1016/j.appet.2018.05.129.CrossRefPubMed

114.

Payahoo L, Khajebishak Y, Asghari Jafarabadi M, Ostadrahimi A. Oleoylethanolamide Supplementation Reduces Inflammation and Oxidative Stress in Obese People: A Clinical Trial. Adv Pharm Bull. 2018;8(3):479–87. https://doi.org/10.15171/apb.2018.056.CrossRefPubMedPubMedCentral

115.

Tutunchi H, Ostadrahimi A, Saghafi-Asl M, et al. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes. Pharmacol Res. 2020;156:104770. https://doi.org/10.1016/j.phrs.2020.104770.CrossRefPubMed

Title: The endocannabinoid system in the adipose organ
Publication date: 01-02-2022
Keywords: Obesity
Obesity
Cannabinoid
Lipolysis
Lipolysis
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 1/2022
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-020-09623-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The endocannabinoid system in the adipose organ

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review

The endocrine role of brown adipose tissue: An update on actors and actions

ATP-consuming futile cycles as energy dissipating mechanisms to counteract obesity

Transplantation of fat tissues and iPSC-derived energy expenditure adipocytes to counteract obesity-driven metabolic disorders: Current strategies and future perspectives

Intercellular and interorgan crosstalk through adipocyte extracellular vesicles

Adipogenic progenitors in different organs: Pathophysiological implications

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page